UNSPSC 51393003: Piquizil

This classification denotes a bronchodilator with the molecular formula C19H26N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K46616F1O, chemically known as 4-(6,7-dimethoxyquinazolin-4-yl)piperazine-1-carboxylic acid isobutyl ester but generally known as piquizil, which bears US NIH Compound Identifier 192994. European Medicines Agency schedules piquizil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09891MIG. Most nations schedule piquizil under HS 29335995 and SITC 51576.

As of Q4 2014, PIQUIZIL remains the US FDA Preferred Term for this commodity. SMILES: CC(C)COC(=O)N1CCN(CC1)C2=NC=NC3=CC(=C(C=C32)OC)OC.

UNSPSC 51393003 Piquizil is a Commodity code under which state and local governments procure naloxone and drug deactivation systems for public health emergency response and community overdose prevention programs. Recent solicitations show this code covers the supply of pharmaceutical intervention products—specifically naloxone (opioid reversal agent) and safe drug deactivation systems—delivered on a scheduled basis to support county and state health initiatives. The work attracts county health departments and state health agencies as primary issuing bodies, with procurement structured around competitive bidding for annual or recurring supply contracts that include delivery, storage, and compliance requirements tied to federal funding streams such as FEMA.

Activity under this code is concentrated in Florida and Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023, under a two-year term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting pathways between state pharmacy benefit programs and pharmaceutical manufacturers, with responses due April 3, 2026. Both solicitations impose E-Verify compliance, insurance and bonding requirements, and compliance with federal environmental regulations where FEMA or similar funding applies.